Intended for US Healthcare Professionals Only

Important Safety Information » | Full Prescribing Information »

ABOUT KEDRAB
DOSAGE AND ADMINISTRATION
ORDERING AND REIMBURSEMENT
ABOUT RABIES AND PEP
RESOURCES
FAQS

ABOUT KEDRAB
DOSAGE AND ADMINISTRATION
ORDERING AND REIMBURSEMENT
ABOUT RABIES AND PEP
RESOURCES
FAQS

SITEMAP

About KEDRAB ❯

Dosage & Administration ❯

Why Volume Matters

Dose Calculator

HRIG Administration Video

Storage & Handling

Ordering and Reimbursement ❯

About Rabies ❯

Rabies Prevalence

Post-exposure Prophylaxis

Patient Profiles

Resources ❯

Rabies Prevention Scenarios

KEDRAB Assurance Program

Product Monograph

Professional Organizations

FAQs ❯

Post-exposure Prophylaxis

Important Safety Information

Full Prescribing Information

Expand

INDICATIONS AND USAGE

KEDRAB is a human rabies immune globulin (HRIG) indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection to persons of all ages when given immediately after contact with a rabid or possibly rabid animal. KEDRAB should be administered concurrently with a full course of rabies vaccine.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:
Patients who can document previous complete rabies pre-exposure prophylaxis or complete post-exposure prophylaxis should only receive a booster rabies vaccine without KEDRAB because KEDRAB may interfere with the anamnestic response to the rabies vaccine.

HYPERSENSITIVITY REACTIONS:
Hypersensitivity reactions, including anaphylaxis, may occur with KEDRAB. IgA deficient patients with antibodies against IgA are at greater risk. Have epinephrine available immediately to treat any acute severe hypersensitivity reactions.

LIVE ATTENUATED VIRUS VACCINES:
KEDRAB administration may interfere with the development of an immune response to live attenuated virus vaccines. If feasible, delay immunization with measles vaccine for 4 months, and other live attenuated virus vaccines for 3 months, after KEDRAB administration.

INTERFERENCE WITH SEROLOGICAL TESTING:
A transient rise of the various passively transferred antibodies in the patient’s blood may result in misleading positive results of serologic tests after KEDRAB administration.
Passive transmission of antibodies to erythrocyte antigens, e.g., A, B, and D, may interfere with serologic tests for red cell antibodies such as the antiglobulin test (Coombs’ test).

TRANSMISSIBLE INFECTIOUS AGENTS:
Because KEDRAB is made from human plasma donors hyper-immunized with rabies vaccine, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. All infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Kedrion Biopharma Inc. at 1-855-353-7466.

ADVERSE REACTIONS:
The most common adverse reactions in adult subjects treated with KEDRAB in clinical trials were injection site pain, headache, muscle pain, joint pain, dizziness, and fatigue.

In pediatric subjects treated with KEDRAB and a full course of rabies vaccine, the most common adverse reactions were injection site pain, headache, fever, pain in extremity, bruising (hematoma), fatigue, and vomiting.
Less common adverse reactions (≤5%) in pediatric patients were injection site redness (erythema), injection site swelling (edema), muscle pain, oral pain, and wound complication. Insomnia was reported as a less common adverse reaction (<5%) in pediatric patients occurring after 14 days of administration.

DRUG INTERACTIONS:
Patients who can document previous complete rabies pre-exposure prophylaxis or complete post-exposure prophylaxis and have a confirmed adequate rabies antibody titer should receive only a booster rabies vaccine (without KEDRAB) because KEDRAB may interfere with the anamnestic response to the vaccine (ACIP).
KEDRAB can interfere with the immune response to the rabies vaccine. For this reason, do not exceed the recommended KEDRAB dose or give additional (repeat) doses of KEDRAB once rabies vaccination has been initiated.
KEDRAB can inactivate the rabies vaccine. For this reason, do not administer KEDRAB in the same syringe as the rabies vaccine or near the anatomical site of administration of the rabies vaccine.

To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-353-7466 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Click here for full Prescribing Information.

Kedrion Biopharma Customer Service

Phone: 1-855-353-7466

Email: US_CustomerService@kedrion.com

Fax: 1-855-751-7951

KEDRAB 360° Program

Sign up for access to educational tools and resources on all things rabies.

About KEDRAB

Dosage & Administration

Why Volume Matters

Dose Calculator

HRIG Administration Videos

Storage & Handling

Ordering and Reimbursement

About Rabies

Rabies Prevalence

Post-exposure Prophylaxis

Patient Profiles

Resources

Rabies Prevention Scenarios

KEDRAB Assurance Program

Product Monograph

Professional Organizations

FAQs

Post-exposure Prophylaxis

Important Safety Information

Full Prescribing Information

Privacy Policy | Terms of Use | Contact | Sitemap | ©2024 Kedrion Biopharma Inc. All Rights Reserved. 2023

KER.0029.USA.23